Phibro Animal Health Corporation
$33.29-$0.79 (-2.3%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.3B
- P/E
- 27.8x
- EV / EBITDA
- 13.8x
- Revenue
- $1.3B
- Net margin
- 3.7%
- ROCE
- 10.1%
Price chart
Technical chartScreen technicals →-18.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -14.2%
- 3M
- -5.4%
- 6M
- -1.5%
- 1Y
- -18.4%
- 5Y
- +52.8%
52-week range
Day change -$0.79 (-2.3%) from $34 to $33 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in PAHC, bought on each weekday since 2021.
News & filings
What Phibro Animal Health filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernDebt is 2.67 times shareholders' equity.
Strengths (1)
- Return on equity rose from 0.9% to 16.9% between fiscal 2024 and fiscal 2025.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Read moreShow less
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
- Sector
- Healthcare
- Shares outstanding
- 40.5M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.3B
- P/E
- 27.8x
- P/B
- 4.7x
- EV / EBITDA
- 13.8x
- EV / Sales
- 1.6x
- P/S
- 1.0x
- 52-week high
- $59.58
- 52-week low
- $28.52
Profitability
- Operating margin
- 8.5%
- Net margin
- 3.7%
- EBITDA margin
- 11.3%
- ROE
- 16.9%
- ROCE
- 10.1%
- ROA
- 3.5%
- Asset turnover
- 0.95
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $1.3B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 27.4%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 11.2%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 1897.7%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $41.8M
Solvency
- Current ratio
- 2.76
- Debt / Equity
- 2.67
- Debt / Assets
- 0.56
- CFO / Net profit
- 1.66
- Cash / Market cap
- 5.7%
Where the revenue went
Of every $100 of FY2025 revenue, $4 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $896.3M |
| Revenue | Gross profit | $399.9M |
| Gross profit | Selling, general and administrative | $289.5M |
| Gross profit | Other operating expenses | $0.00 |
| Gross profit | Operating income | $110.5M |
| Operating income | Pretax income | $68.0M |
| Operating income | Interest and other expense | $42.5M |
| Pretax income | Tax and other | $19.7M |
| Pretax income | Net income | $48.3M |
Revenue and net profit
Revenue grew 27.4% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $942.3M | $49.2M |
| FY2023 | $977.9M | $32.6M |
| FY2024 | $1.0B | $2.4M |
| FY2025 | $1.3B | $48.3M |
Cash flows
FY2025: $80.1M from operations, $41.8M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $31.6M | -$5.4M |
| FY2023 | $13.3M | -$38.5M |
| FY2024 | $87.6M | $46.4M |
| FY2025 | $80.1M | $41.8M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $1.3B+27.4%1Y
- EBITDA
- $146.8M+112.6%1Y
- Net profit
- $48.3M+1,897.7%1Y
- Cash from operations
- $80.1M-8.5%1Y
- Free cash flow
- $41.8M-9.8%1Y
- Revenue CAGR, 3Y
- 11.2%
- Net profit CAGR, 3Y
- -0.6%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.3B | $146.8M | $48.3M | $41.8M | 16.9% | +27.4% | +1897.7% |
Monthly returns
Month-by-month returns of PAHC across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.4B |
| Current assets | $810.6M |
| Non-current assets | $550.3M |
| Liabilities | $1.1B |
| Current liabilities | $293.5M |
| Non-current liabilities | $781.7M |
| Equity | $285.7M |
| Paid-in capital | $137.0M |
| Retained earnings | $272.7M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; PAHC highlighted.
P/E against peers
PAHC trades at 27.8x earnings against a peer median of 11.9x (a 132% premium).
Not shown (no positive earnings and no EV / Sales): Acadia Healthcare Company, Inc., Neogen Corporation, Sarepta Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Phibro Animal Health CorporationPAHCthis companyP/E ↑ premium | $1.3B | 27.8x | 4.7x | 16.9% | 13.8x |
| TransMedics Group, Inc.TMDX | $2.5B | 13.0x | 5.2x | 40.2% | 16.8x |
| Acadia Healthcare Company, Inc.ACHC | $2.3B | -2.1x | 1.2x | -56.6% | -6.5x |
| Prestige Consumer Healthcare Inc.PBH | $2.2B | 11.3x | 1.1x | 10.1% | 9.5x |
| LeMaitre Vascular, Inc.LMAT | $2.1B | 37.0x | 5.4x | 14.7% | 25.3x |
| Select Medical Holdings CorporationSEM | $2.0B | 14.0x | 1.2x | 8.6% | 9.2x |
| Neogen CorporationNEOG | $2.0B | -1.8x | 1.0x | -52.7% | -2.9x |
| ADMA Biologics, Inc.ADMA | $1.8B | 12.6x | 3.9x | 30.8% | 9.3x |
| Sarepta Therapeutics, Inc.SRPT | $1.8B | -2.5x | 1.5x | -62.5% | -3.2x |
| Peer median | — | 11.9x | 1.4x | 9.3% | 9.3x |
Year-to-date ROI
PAHC since 1 January, against earlier years.
Historical volatility
PAHC's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 8.4% |
| FY2023 | 7.3% |
| FY2024 | 5.2% |
| FY2025 | 8.5% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $1.3B |
| Cost of revenueCost Of Revenue | $896.3M |
| Gross profitGross Profit | $399.9M |
| Operating expensesOperating Expense | $289.5M |
| Selling, general and administrativeSelling General And Administration | $289.5M |
| Total expensesTotal Expenses | $1.2B |
| Operating incomeOperating Income | $110.5M |
| Interest and other | |
| Pretax incomePretax Income | $68.0M |
| TaxTax Provision | $19.7M |
| Net incomeNet Income | $48.3M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.4B |
| Current assetsCurrent Assets | $810.6M |
| Non-current assetsTotal Non Current Assets | $550.3M |
| LiabilitiesTotal Liabilities Net Minority Interest | $1.1B |
| Current liabilitiesCurrent Liabilities | $293.5M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $781.7M |
| EquityTotal Equity Gross Minority Interest | $285.7M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $80.1M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $80.1M |
| Net income, continuing operationsNet Income From Continuing Operations | $48.3M |
| Depreciation and amortisationDepreciation And Amortization | $45.6M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $45.6M |
| Depreciation | $37.8M |
| Amortization cash flowAmortization Cash Flow | $7.8M |
| Amortization of intangiblesAmortization Of Intangibles | $7.8M |
| Stock-based compensationStock Based Compensation | $720.0k |
| Deferred taxDeferred Tax | -$4.9M |
| Deferred income taxDeferred Income Tax | -$4.9M |
| Operating gains and lossesOperating Gains Losses | $600.0k |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | $600.0k |
| Asset impairmentAsset Impairment Charge | $5.3M |
| Pension and employee benefit expensePension And Employee Benefit Expense | $0.00 |
| Change in working capitalChange In Working Capital | -$21.6M |
| Other non-cash itemsOther Non Cash Items | $6.0M |
| Investing cash flowInvesting Cash Flow | -$288.7M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$288.7M |
| Capital expenditureCapital Expenditure | -$38.3M |
| Capital expenditure (reported)Capital Expenditure Reported | -$38.3M |
| AcquisitionsPurchase Of Business | -$286.5M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$286.5M |
| Purchase of investmentsPurchase Of Investment | -$14.0M |
| Sale of investmentsSale Of Investment | $49.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | $35.0M |
| Other investing changesNet Other Investing Changes | $1.1M |
| Financing cash flowFinancing Cash Flow | $207.1M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $207.1M |
| Debt issuedIssuance Of Debt | $1.2B |
| Debt repaidRepayment Of Debt | -$946.0M |
| Net debt issuedNet Issuance Payments Of Debt | $236.0M |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $1.2B |
| Long-term debt repaidLong Term Debt Payments | -$946.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | $236.0M |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | — |
| Dividends paidCash Dividends Paid | -$19.4M |
| Common dividends paidCommon Stock Dividend Paid | -$19.4M |
| Other financing chargesNet Other Financing Charges | -$9.4M |
| Change in cashChanges In Cash | -$1.4M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | -114.0% |
| Cash at the start of the yearBeginning Cash Position | $70.6M |
| Cash at the end of the yearEnd Cash Position | $68.0M |
| Free cash flowFree Cash Flow | $41.8M |
| Supplemental |
Learn while you research
Academy chapters picked for Phibro Animal Health Corporation and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing27% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Leverage RatiosDebt/Equity of 2.67 is elevated, understand what that means for solvency.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read